PL4054582T3 - Terapeutyczne kombinacje akalabrutynibu i kapiwasertybu w leczeniu nowotworów z komórek b - Google Patents
Terapeutyczne kombinacje akalabrutynibu i kapiwasertybu w leczeniu nowotworów z komórek bInfo
- Publication number
- PL4054582T3 PL4054582T3 PL20800617.1T PL20800617T PL4054582T3 PL 4054582 T3 PL4054582 T3 PL 4054582T3 PL 20800617 T PL20800617 T PL 20800617T PL 4054582 T3 PL4054582 T3 PL 4054582T3
- Authority
- PL
- Poland
- Prior art keywords
- cell
- menocorisms
- capivasertib
- acalabrutinib
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930208P | 2019-11-04 | 2019-11-04 | |
| PCT/EP2020/080493 WO2021089419A1 (en) | 2019-11-04 | 2020-10-30 | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4054582T3 true PL4054582T3 (pl) | 2026-02-16 |
Family
ID=73043259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20800617.1T PL4054582T3 (pl) | 2019-11-04 | 2020-10-30 | Terapeutyczne kombinacje akalabrutynibu i kapiwasertybu w leczeniu nowotworów z komórek b |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12691113B2 (pl) |
| EP (1) | EP4054582B1 (pl) |
| JP (1) | JP7575454B2 (pl) |
| KR (1) | KR102984130B1 (pl) |
| CN (1) | CN114728003B (pl) |
| AU (1) | AU2020381240C1 (pl) |
| CA (1) | CA3158321A1 (pl) |
| DK (1) | DK4054582T3 (pl) |
| ES (1) | ES3055126T3 (pl) |
| FI (1) | FI4054582T3 (pl) |
| MX (1) | MX2022005250A (pl) |
| PL (1) | PL4054582T3 (pl) |
| PT (1) | PT4054582T (pl) |
| WO (1) | WO2021089419A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023230286A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| WO2024104561A1 (en) * | 2022-11-15 | 2024-05-23 | Astrazeneca Ab | Therapeutic combinations of capivasertib and venetoclax |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| CN103889987B (zh) | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
| AU2014360537B2 (en) * | 2013-12-04 | 2017-09-07 | Gilead Sciences, Inc. | Methods for treating cancers |
| EP3076974A1 (en) * | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| JP6785804B2 (ja) * | 2015-06-23 | 2020-11-18 | ギリアド サイエンシズ， インコーポレイテッド | Ｂ細胞悪性腫瘍を治療するための組合せ療法 |
| US20170071962A1 (en) | 2015-09-11 | 2017-03-16 | Acerta Pharma B.V. | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor |
| BR112017002594A2 (pt) * | 2015-12-17 | 2017-12-19 | Gilead Sciences Inc | compostos inibidores de cinase de ligação de tank |
| CN107344940B (zh) * | 2016-05-06 | 2020-04-21 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| AU2018335617B2 (en) * | 2017-09-25 | 2021-12-09 | Astrazeneca Ab | Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| KR20250119664A (ko) | 2018-08-29 | 2025-08-07 | 아세르타 파마. 비.브이. | 4-｛8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일｝N-(피리딘-2-일)-벤즈아미드의제조 공정 |
-
2020
- 2020-10-30 DK DK20800617.1T patent/DK4054582T3/da active
- 2020-10-30 CN CN202080076132.6A patent/CN114728003B/zh active Active
- 2020-10-30 CA CA3158321A patent/CA3158321A1/en active Pending
- 2020-10-30 KR KR1020227018891A patent/KR102984130B1/ko active Active
- 2020-10-30 US US17/755,548 patent/US12691113B2/en active Active
- 2020-10-30 FI FIEP20800617.1T patent/FI4054582T3/fi active
- 2020-10-30 PT PT208006171T patent/PT4054582T/pt unknown
- 2020-10-30 ES ES20800617T patent/ES3055126T3/es active Active
- 2020-10-30 PL PL20800617.1T patent/PL4054582T3/pl unknown
- 2020-10-30 WO PCT/EP2020/080493 patent/WO2021089419A1/en not_active Ceased
- 2020-10-30 AU AU2020381240A patent/AU2020381240C1/en active Active
- 2020-10-30 EP EP20800617.1A patent/EP4054582B1/en active Active
- 2020-10-30 MX MX2022005250A patent/MX2022005250A/es unknown
- 2020-10-30 JP JP2022525916A patent/JP7575454B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7575454B2 (ja) | 2024-10-29 |
| JP2023501317A (ja) | 2023-01-18 |
| EP4054582B1 (en) | 2025-09-03 |
| FI4054582T3 (fi) | 2025-12-04 |
| CA3158321A1 (en) | 2021-05-14 |
| KR20220098175A (ko) | 2022-07-11 |
| EP4054582A1 (en) | 2022-09-14 |
| DK4054582T3 (da) | 2025-12-01 |
| PT4054582T (pt) | 2025-12-10 |
| AU2020381240C1 (en) | 2024-02-15 |
| WO2021089419A1 (en) | 2021-05-14 |
| AU2020381240A1 (en) | 2022-06-23 |
| US20220401442A1 (en) | 2022-12-22 |
| KR102984130B1 (ko) | 2026-07-01 |
| CN114728003A (zh) | 2022-07-08 |
| US12691113B2 (en) | 2026-07-28 |
| AU2020381240B2 (en) | 2023-09-07 |
| MX2022005250A (es) | 2022-06-08 |
| ES3055126T3 (en) | 2026-02-10 |
| CN114728003B (zh) | 2025-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE058931T2 (hu) | Pilokarpin hidroklorid alkalmazása presbyopia kezelésére | |
| IL283149A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| DK3849534T3 (da) | Kombination af dasatinib og adagrasib til anvendelse i behandling af ikke-småcellet lungecancer | |
| HUE066282T2 (hu) | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra | |
| MA46716A (fr) | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie | |
| DK4014976T3 (da) | Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan | |
| DK3322425T3 (da) | Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi | |
| MA52542A (fr) | Thérapie cellulaire adoptive | |
| IL286334A (en) | Modified micrornas and their use in the treatment of cancer | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| IL284053A (en) | New compounds and their use in therapy | |
| PT3615035T (pt) | Utilização de 20-hidroxiecdisona e os seus derivados no tratamento de miopatias | |
| IL268210A (en) | Use of gaboxadol in the treatment of tinnitus | |
| IL281100A (en) | Methods of modulating m2 macrophage polarization and use of same in therapy | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL282703A (en) | Novel compounds useful for treating cardiovascular diseases | |
| DK3920960T3 (da) | Behandling med car-manipulerede t-celler og cytokiner | |
| PL3678692T3 (pl) | Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy | |
| GB201700692D0 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
| IL280453B2 (en) | History of benzenesulfonamide-phenyl-alkyloxy-alkyl acids and their use in therapy. | |
| PL3630112T3 (pl) | Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu | |
| IL277805A (en) | Use of gaboksadol in the treatment of substance use disorders | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| PL3476397T3 (pl) | Nowe kompozycje i ich zastosowanie w leczeniu zakażeń bakteryjnych | |
| GB2574747B (en) | Use of lambda interferons in the treatment of obesity-related disorders and related diseases |